AngioDynamics (NASDAQ:ANGO) Stock Rating Cut to Hold at Wall Street Zen

Key Points

• Wall Street Zen downgraded AngioDynamics to “Hold”, although the broader analyst consensus remains “Moderate Buy” with an average price target of $19.50.
• AngioDynamics beat fiscal Q1 2027 expectations, reporting a $0.04 adjusted EPS loss versus the anticipated $0.11 loss and revenue of $80.92 million. Med Tech sales and gross margins improved, but the company still posted a $7.1 million GAAP loss and negative operating cash flow.
• Leadership and profitability remain risks: Eric Honroth is set to become CEO on November 2, while fiscal 2027 guidance still calls for an adjusted EPS loss of $0.24 to $0.29.

AngioDynamics (NASDAQ:ANGO - Get Free Report) was downgraded by Wall Street Zen from a "buy" rating to a "hold" rating in a research note issued to investors on Saturday, Wall Street Zen reports.

Several other equities research analysts have also recently weighed in on ANGO. Canaccord Genuity Group reaffirmed a "buy" rating and set a $20.00 price objective on shares of AngioDynamics in a research report on Friday. Zacks Research raised shares of AngioDynamics from a "strong sell" rating to a "hold" rating in a report on Monday, October 5th. Weiss Ratings restated a "sell (d-)" rating on shares of AngioDynamics in a research report on Friday, July 17th. Finally, HC Wainwright upped their price target on shares of AngioDynamics from $16.00 to $19.00 and gave the stock a "buy" rating in a report on Wednesday, July 15th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $19.50.

AngioDynamics Price Performance

Shares of NASDAQ:ANGO opened at $11.52 on Friday. The business's 50 day simple moving average is $15.32 and its 200 day simple moving average is $13.10. AngioDynamics has a 1 year low of $9.39 and a 1 year high of $16.29. The company has a market capitalization of $484.46 million, a P/E ratio of -14.77 and a beta of 0.30.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last announced its quarterly earnings data on Thursday, October 8th. The medical instruments supplier reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.07. The firm had revenue of $80.92 million during the quarter, compared to analysts' expectations of $80.51 million. AngioDynamics had a negative return on equity of 4.43% and a negative net margin of 10.12%. AngioDynamics has set its FY 2027 guidance at -0.290--0.240 EPS. On average, sell-side analysts anticipate that AngioDynamics will post -0.25 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, SVP Warren Jr sold 23,370 shares of the firm's stock in a transaction dated Thursday, July 30th. The stock was sold at an average price of $14.72, for a total value of $344,006.40. Following the sale, the senior vice president directly owned 64,745 shares of the company's stock, valued at $953,046.40. This trade represents a 26.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. 6.00% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. BlackRock Inc. acquired a new stake in shares of AngioDynamics in the 2nd quarter valued at approximately $49,480,000. Armistice Capital LLC increased its position in AngioDynamics by 3.9% during the 4th quarter. Armistice Capital LLC now owns 1,700,000 shares of the medical instruments supplier's stock worth $21,828,000 after purchasing an additional 64,000 shares in the last quarter. Weber Capital Management LLC ADV acquired a new position in AngioDynamics during the 2nd quarter worth approximately $17,649,392. Bastion Asset Management Inc. lifted its stake in AngioDynamics by 17.4% in the 1st quarter. Bastion Asset Management Inc. now owns 1,313,002 shares of the medical instruments supplier's stock valued at $14,107,000 after purchasing an additional 194,822 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its stake in AngioDynamics by 3.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 948,815 shares of the medical instruments supplier's stock valued at $10,786,000 after purchasing an additional 32,476 shares during the last quarter. Institutional investors and hedge funds own 89.43% of the company's stock.

Trending Headlines about AngioDynamics

Here are the key news stories impacting AngioDynamics this week:

• Positive Sentiment: Adjusted earnings beat expectations. AngioDynamics reported fiscal Q1 2027 adjusted EPS of a $0.04 loss, better than the $0.11 loss analysts expected. Revenue reached $80.9 million, slightly above consensus and up 6.9% year over year. Zacks earnings report
• Positive Sentiment: Med Tech growth and margins were strong. Med Tech sales rose 13.2% to $39.9 million, led by 14.7% growth in Auryon sales and 29% growth in NanoKnife sales. Gross margin expanded 410 basis points to 59.4%, while the GAAP net loss narrowed from the prior year. The company also received FDA IDE approval for a NanoKnife feasibility study in benign prostatic hyperplasia. AngioDynamics fiscal Q1 results
• Positive Sentiment: Canaccord reaffirmed its Buy rating and set a $20 price target, implying substantial potential upside from the referenced share price. Benzinga report
• Neutral Sentiment: Fiscal 2027 guidance was reiterated: revenue of $336 million to $341 million and an adjusted EPS loss of $0.24 to $0.29. The outlook remains broadly in line with analyst expectations, but it does not yet indicate a return to profitability. Seeking Alpha guidance report
• Negative Sentiment: Leadership uncertainty is weighing on sentiment. Eric Honroth will become president and CEO on November 2, succeeding Jim Clemmer. The transition adds execution risk even as operating momentum improves. CEO appointment announcement
• Negative Sentiment: Profitability and cash flow remain concerns. AngioDynamics posted a GAAP net loss of $7.1 million and used $15.3 million of operating cash during the quarter. These issues likely overshadowed the adjusted EPS and revenue beats. Reported short-interest data showing zero shares appears inconsistent and should be treated cautiously.

AngioDynamics Company Profile

AngioDynamics, Inc is a medical device company that develops, manufactures and markets minimally invasive products for use in vascular disease, vascular access and oncology. Its technologies are designed to help physicians treat blood clots, restore blood flow, manage vascular access and ablate targeted tissue.

The company's portfolio includes the Auryon platform for atherectomy, which uses laser technology to treat peripheral arterial disease; the AngioVac and AlphaVac systems for removing thrombus and other unwanted material from blood vessels; and BioSentry products used to seal biopsy tracts.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.